Fazirsiran and Screening for AATD Liver Disease, With Pavel Strnad, MD

Pooled analysis of two phase 2 clinical trials shows that the siRNA therapy fazirsiran significantly reduces liver Z-AAT levels and inflammation in patients with alpha-1 antitrypsin deficiency-associated liver disease. The treatment demonstrated a favorable safety and efficacy profile over the study period.
Why it matters
This research offers a potential breakthrough for patients suffering from a rare genetic liver disease, providing a targeted molecular therapy to address the underlying cause of the condition.
Fazirsiran 200 mg reduced intrahepatic Z-AAT by approximately 90% and improved liver enzymes and portal inflammation compared with placebo in adults with alpha-1 antitrypsin deficiency-associated liver disease (AATD-LD) and a Pi*ZZ genotype, according to pooled analyses of 2 phase 2 trials presented at AASLD The Liver Meeting 2026.¹
Pavel Strnad, MD, of University Hospital RWTH Aachen, presented the data and discussed them in an interview with HCPLive. He noted the individual phase 2 trials of the small interfering RNA (siRNA) therapy were small, and pooling them made the treatment effect clearer.
How Did Fazirsiran Affect Z-AAT Burden and Portal Inflammation?
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in